Wide range of therapeutic applications for venetoclax/venetoclax

Venetoclax/Venetoclax, as a revolutionary targeted therapy drug, has demonstrated remarkable effects in the treatment of various hematological malignancies.

1. Treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL):

Veneclar has become a highly recommended treatment for adults with chronic lymphocytic leukemia or small lymphocytic lymphoma. These two common types of leukemia can weaken a patient's immune system, increase the risk of infection, and even cause other major health problems. The unique mechanism of venetoclax is that it can interfere with the function of B-cell lymphoma 2 (BCL-2) protein, thereby guiding the patient's white blood cells to return to normal levels and significantly improve the condition.

2. Combination therapy for acute myeloid leukemia (AML):

In the face of acute myeloid leukemia, a rapidly progressing disease, venetoclax has also demonstrated its therapeutic potential. AML causes the bone marrow to abnormally produce white blood cells, disrupting the normal hematopoietic mechanism. In this situation, venetoclax is often combined with other drugs, such as azacitidine, decitabine or low-dose cytarabine, to form a powerful treatment lineup. Especially for elderly patients aged 75 and above, or those who cannot tolerate intensive induction chemotherapy, this combination therapy can effectively control the progression of AML and significantly improve the patient's survival rate and quality of life.

Overall, venetoclax has demonstrated excellent efficacy and reliable safety in the treatment of chronic lymphocytic leukemia, small lymphocytic lymphoma and acute myeloid leukemia.